Dr. Goy on the Potential Utility of Liso-Cel in MCL
In Partnership With:
Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.
Andre H. Goy, MD, Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service, Chairman & Chief Physician Officer - John Theurer Cancer Center, Lydia Pfund Chair for Lymphoma, Academic Chairman Oncology - Hackensack Meridian School of Medicine, Professor of Medicine – Georgetown University, Hackensack, NJ, discusses the potential utility of lisocabtagene maraleucel (liso-cel; Breyanzi) in mantle cell lymphoma (MCL).
During the 2020 ASH Annual Meeting and Exposition, findings from the phase 1 TRANSCEND-NHL-001 trial demonstrated an objective response rate of 84% and a complete response rate of 66% with liso-cel in 32 patients with relapsed/refractory MCL.
Moreover, compared with the results of the phase ZUMA-2 trial with brexucabtagene autoleucel (Tecartus), liso-cel appeared to demonstrate fewer cases of grade 3 or higher cytokine release syndrome and neurotoxicity, says Goy.
Although the CAR T-cell therapy is not approved to treat patients with relapsed/refractory MCL, liso-cel could provide another option that leads to durable responses in elderly patients with MCL who would otherwise have limited treatment options, concludes Goy.
